Across the four TNF-α inhibitors, we identified 36 Preferred Terms (PTs) associated with infective pneumonia-related adverse events, with infliximab having the highest number of PTs and golimumab the lowest. The gene discussed is TNF; the disease is susceptibility to pneumonia measurement.